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Abstract. Progressive liver failure or hepatic complica-
tions of the primary disease led to orthotopic liver trans-
plantation in eight children with glycogen storage dis-
ease over a 9-year period. One patient had glycogen 
storage disease (GSD) type I (von Gierke disease) and 
seven patients had type IV GSD (Andersen disease). As 
previously reported [19], a 16.5-year-old-girl with GSD 
type I was successfully treated in 1982 by orthotopic liver 
transplantation under cyclosporine and steroid immuno-
suppression. The metabolic consequences of the disease 
have been eliminated, the renal function and size have 
remained normal, and the patient has lived a normal 
young adult life. A late portal venous thrombosis was 
treated successfully with a distal splenorenal shunt. Or-
thotopic liver transplantation was performed in seven 
children with type N GSD who had progressive hepatic 
failure. Two patients died early from technical complica-
tions. The other five have no evidence of recurrent he-
patic amylopectinosis after 1.1-5.8 postoperative years. 
They have had good physical and intellectual matura-
tion. Amylopectin was found in many extrahepatic tis-
sues prior to surgery, but cardiopathy and skeletal myo-
pathy have not developed after transplantation. Post-
operative heart biopsies from patients showed either 
minimal amylopectin deposits as long as 4.5 years fol-
lowing transplantation or a dramatic reduction in se-
quential biopsies from one patient who initially had dense 
myocardial deposits. Serious hepatic derangement is seen 
most commonly in types T and IV GSD. Liver transplan-
tation cures the hepatic manifestations of both types. 
The extrahepatic deposition of abnormal glycogen ap-
pears not to be problematic in type I disease, and while 
potentially more threatening in type IV disease, may ac-
tually exhibit signs of regression after hepatic allograft-
ing. 
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Introduction 
By evaluation of products of hepatic synthesis such as 
haptoglobin [17. 22, 29] group specific component [17, 
18], and others [1,2,24,32,36] it has been demonstrated 
that liver homografts retain their original metabolic spec-
ificity after liver transplantation. It has been well recog-
nized that hepatic transplantation has been effective in 
the treatment of certain inborn errors of metabolism that 
result partly or completely from defects in hepatic func-
tion [18]. Some of these, notably the glycogenoses, also 
result in anatomic impairment of the liver and progres-
sive liver failure. 
Type I glycogen storage disease (GSD) results in gly-
cogen overloading in liver, kidney, and intestinal cells 
which are deficient in glucose 6 phosphatase [8, 23]. 
Hypoglycemia, deficient gluconeogenesis, and accumu-
lation of lactic acid underlie the clinical manifestations of 
seizures, systemic acidosis, hyperlipidemia, and growth 
retardation [10]. Such pre-operative clinical signs pre-
vailed in the first patient that was transplanted for type I 
GSD nearly 9 years ago. 
In Type IV GSD (Andersen disease, amylopectino-
sis) [3], branching enzyme alpha-I, 4-glucan: alpha-I,4-
glucan 6-g1ycosyl transferase activity is notably absent in 
hepatic tissue as well as in cultured skin fibroblasts and 
other tissues [6, 15]. Fatal hepatic complications usually 
occur by the age of 2-4 years, but in exceptional cases 
involvement in other organ systems may be prominent 
mortality factors [4, 5, 12, 14,27,35]. Liver transplanta-
tion for this disease was first attempted in 1972, but the 
recipient died 110 days later after uncontrolled rejection 
of his first liver and attempted retransplantation [31]. 
The first successful liver replacement was in September 
1984 in patient 1 of the present series, and since then, we 
have made six more such attempts. These seven cases 
are the basis of this report. 
Methods 
Type IGSD 
This liver recipient was diagnosed clinically and histolog-
ically at age 2.5 years and transplanted at age 16.5. An 
older sibling had died in infancy with the same disease. 
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Table 1. Clinical data of patients with type IV glycogen storage dis-
ease undergoing liver transplantation 
Patient Age (months) at Skin fibroblast Survival 
1 a 
2 
3b 
4 
5b 
6a 
7 
a Siblings 
b Siblings 
transplantation branching en-
31 
11 
36 
46 
22 
20 
34 
zyme activityC 
E~lmoles/min/mgF 
0.10 
0.07 
0.11 
0.11 
0.08 
CJ.06 
0.09 
73 months 
Died 7 days 
after LTx 
Died 36 days 
afterLTx 
58 months 
35 months 
18 months 
16 months 
C Normal branching enzyme activity in skin fibroblasts: 1 to 2 
Ilmoles/min/mg protein [2. 4] 
Type IVGSD 
The seven liver transplantations were performed between 
6 September 1984 and 26 May 1989 (Table 1). All pa-
tients were males with two sets of brothers. The mean 
age at diagnosis was 11 months (range prenatal to 24 
months) and the mean age at the time of transplantation 
was 29 months (11-46). The mean time from diagnosis 
until transplantation was 16.7 months. 
For both types of glycogenosis, orthotopic liver trans-
plantation was done in the usual fashion, and postopera-
tive immunosuppression was with cyclosporine and pred-
nisone. 
Clinical features 
TypeJGSD 
As a young child the patient had symptoms of recurrent 
hypoglycemia, epistaxis, and growth retardation. Chemi-
cally, she had persistent systemic acidosis, marked trans-
aminase elevation, hyperbilirubinemia and hyperlipid-
emia. End-to-side portacaval shunting at age 8 amelior-
ated most of the symptoms except for the hypoglycemia, 
and her clinical course until liver transplantation was 
characterized by persistent feeding problems. Continu-
ous night-time feedings and occasional hyperalimenta-
tion were employed. In addition to massive hepatospleno-
megaly the patient developed multiple hepatic adeno-
mas evident on liver scanning. These became apparent 
about 2 years before her transplant, and with the pro-
gressive adenomatosis the liver function deteriorated 
and her encephalopathy worsened. 
Type JVGSD 
Ascites and growth delays were always noted. In all of 
the children, hepatomegaly and splenomegaly were mas-
sive, and there were persistent moderate to marked ele-
vations of the transaminases. Bilirubin ranged from 6 to 
170I1mol/l, five of the seven children being jaundiced. 
The degree of liver disease was classified as severe in five 
cases and moderate in two. None of the patients re-
quired treatment preoperatively for hypoglycemia. 
Psychomotor and cardiac assessment 
Type JVGSD 
The percentile height position of the patients on Har-
vard growth charts was < 5 in six of the seven children 
and ten in the other; weight percentiles were distorted 
by ascites and liver mass. Gross and fine motor develop-
ment and language ability generally were retarded in all 
seven patients. No cardiac complaints or abnormal heart 
findings were present preoperatively in any of the seven 
patients. Cardiac biopsies were not obtained, mainly for 
safety reasons, until after transplantation. 
Tissue studies 
Type IGSD 
Multiple hepatic adenomas were present in the native 
liver. Biochemical studies of samples quick frozen at 
- 70°C and stored on dry ice were performed by Dr. Bar-
bara Illingworth Brown, Washington University, St. 
Louis. This showed the glucose 6 phosphatase activity at 
0.08I1m/min per gram liver with control values in the 
range of 3.7-14.4. The liver contained 8.7% glycogen 
(normal <5%). 
Type IVGSD 
Pre-transplant liver biopsies as well as the whole livers 
were examined with light microscopy and showed PAS 
inclusions after diastase digestion. Electron microscopic 
studies demonstrated the fibrillar aggregations that are 
typical of amylopection [16,25,26]. Cultured skin fibro-
Table 2. PAS-diastase positive deposits in the myocardium of four 
patients with type IV glycogen storage disease after liver trans-
plantation 
Patient Time sample No of incl usions Mean % Mean 
(months post- per3.6 x 105 area occu- size of 
transplant) flm2 pied by inclusions 
inclusions (flm2) 
54.0 2-1- 0.5% 140 
3 1.2 46 2 % 141 
(Autopsy) 
6 0.9 332 13 % 146 
14.0 129 5.9% 164 
7 1.0 Too few to 
quantitate 
11.0 Too few to 
quantitate 
blasts and homogenates of liver tissue were assayed at 
Washington University, St. Louis, for branching enzyme 
activity. The phosphorylase coupled assay measured the 
rate of formation of inorganic phosphate from glucose-1-
phosphate as glucose was polymerized to glycogen by 
the homogenates [6, 7, 14]. The branching enzyme activ-
ity in skin fibroblasts averaged 0.08 J-lmoles/min per mg 
protein, which was less than 10% of the activity of nor-
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Fig.lA-D. Heart biopsies from 
patient 6. 3.5 weeks after liver 
transplantation (B, D) and 14 
months later CA, C). Note the 
marked decrease in the number 
of inclusions although many of 
the remainder are large. The 
sections in the A, B panels have 
a more longitudinal arrange-
ment, and those in the C, D 
panels are more cross-sectional. 
The myocardial fibers are slightly 
larger than before. P A5 diastase 
stain. Original magnification 
x 380 
mal controls (Table 1). The liver homogenate results 
were confirmatory (not shown). 
Special morphometric studies were performed on PAS 
diastase stained heart tissue which was obtained at au-
topsy in one patient and with endomyocardial biopsies in 
three others at variable times after transplantation (Ta-
ble 2). The morphometry was done with the Bioquant 
System IV software on an Everex 286/12 computer with 
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SummaSketch Plus eyepiece micrometer (Summa Graph-
ics, 60 Silver Mine Road, Seymour, Connecticut 06483), 
and an Olympus BH-2 microscope. A 200 J.lm x 200 J.lm 
grid at 40 x magnification was randomly placed in multi-
ple locations on each piece of PAS-diastase stained myo-
cardium. Each inclusion was outlined in the field and the 
calculations made by the instrument. To eliminate arte-
fact caused by vessels or compression, interstitial and 
vascular spaces in the field were eliminated from the 
final calculations. Sections were examined which had a 
predominantly longitudinal (Fig. lB. D) or cross-sec-
tional cut (Fig. lA, C). To see the extent of sample 
variations, multiple specimens were examined from a 
large piece of right ventricle obtained at autopsy from 
patient 3. All had much the same amylopectin distri-
bution with the single exception of a superficial sub-
endocardial field. The technology was double checked 
with a point counting method which gave similar re-
sults. 
Results 
Survival 
Type I GSD. Nine years after transplantation this young 
adult continues to demonstrate normal carbohydrate me-
tabolism in both fasting and challenged states (see Figs. 
2,3). She had a late portal venous thrombosis 7 months 
after transplantation which was treated with a distal 
splenorenal shunt and she now has normal bilirubin and 
transaminases. A renal biopsy has not been performed 
since both size and function of the kidneys has been nor-
mal. 
Type IV GSD. Five children (71.4%) survived beyond 
the perioperative period. All five are still alive and heal-
thy after a mean duration of 37.3 months (13.5-70). All 
have normal liver function, and with decompression of 
the portal hypertension via the new liver, the splenomeg-
aly has resolved in all cases. The two deaths were caused 
7 and 36 days postoperatively by septic complications 
from a bowel perforation in one child, and thrombosis of 
the hepatic artery in the other. 
Studies of the transplanted livers 
Type I GSD. Liver biopsy done 4 years after transplanta-
tion showed normal hepatic parenchyma and normal gly-
cogen stores. This is based on a PAS stain showing a uni-
form distribution of fine granular material but varies in 
concentration between 1.5%-5.0% based on the nutri-
tional state. 
Type IV GSD. The liver graft lost from hepatic artery 
thrombosis showed extensive necrosis but contained no 
amylopectin. Autopsy was denied of the child who died 
after 7 days. The normally functioning liver grafts in the 
five surviving children were biopsied from 1-45 months 
postoperatively, as indicated for early management or 
arbitrarily for late follow-up. The livers were normal, 
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Fig. 2. Oral glucose tolerance test at age 8 years and 6 weeks after 
transplantation 
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Fig. 3. Response of blood glucose concentrations during fasting at 
age 8 years, and 6 weeks after liver transplantation 
and with special stains or electron microscopy, there was 
no evidence of amylopectin. 
Cardiac studies 
Type IV GSD. Chest X-ray films, clinical evaluation, 
and serial electrocardiographic and echocardiographic 
testing were done on all surviving children at frequent 
intervals postoperatively. In addition, one child had an 
MRI scan of the heart. No abnormalities were detected. 
After transplantation, samples were available from 
four of the recipients' hearts (Table 2). Amylopectin oc-
cupied about 2% of the area in the myocardium of the 
36-month-old patient who died after 36 days (Table 2). 
Amylopectin was also found in his esophagus, bowel, 
bladder smooth muscle, skeletal muscle, central nervous 
system, and peripheral nerves. 
Patient 1 whose liver replacement was at age 36 
months, had a heart biopsy which was almost free of 
amylopectin 54 months later. His sibling (patient 6) was 
too ill preoperatively for an endomyocardial biopsy, but 
3 weeks after transplantation, a biopsy in the younger 
boy showed involvement of 13% of the myocardial area 
(Table 2). Thirteen months after liver transplantation, a 
repeat heart biopsy showed remarkable improvement 
(Fig. 1) with a reduction of the amylopectin to 5.9% 
(Table 2). In patient 7, the heart biopsy 1 months after 
liver transplantation showed rare deposits in the myo-
cytes; 10 months later, there was no change. 
Psychomotor assessment 
Type IV GSD. An intra-operative skeletal muscle biopsy 
in one of the surviving patients showed light deposits of 
amylopectin. The abnormal polysaccaride also was found 
in three of three intraoperative skin biopsies which in-
cluded erector pili muscles, and in the smooth muscle of 
an excised segment of jejunum of one of these patients. 
However, none of the five survivors has had any evi-
dence of progressive muscular disease. All five had growth 
retardation before transplantation, but have developed 
at a normal rate afterwards, and the three with the lon-
gest postoperative follow ups have advanced into higher 
height or weight percentiles, or both. The physical prow-
ess of all five children has improved. 
Two of the children are performing well in grade 
school. Cognitive skills of the other three pre-school sur-
vivors are rated as good by the parents with no perceived 
abnormalities in intellectual growth. One child who was 
tested with the Gesell test 2 years postoperatively showed 
normal intellectual growth. None of the patients has 
myoclonus, seizures or other signs of abnormal neuro-
motor function. 
Discussion 
Since our initial report of this case in 1983 [19] there has 
only been one other reported case of liver transplanta-
tion for type I GSD [21] and the outcome was similar to 
ours with conversion to normal intermediary carbohy-
drate metabolism and elimination of the other metabolic 
derangements. Hepatic architecture remains normal in 
both patients and no extrahepatic organ dysfunction due 
to the glycogen deposition has been described in either 
case. 
With respect to type IV GSD most of the clinical re-
ports have emphasized variable but usually early hepatic 
manifestations [4, 5,14]. However, all glycogen contain-
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ing cells can be affected as was illustrated in the compo-
site of tissue from our patients. The liver is usually the 
earliest casualty, but there can be an array of clinical 
presentations depending on the dominant organ system 
affected. Occasional cases of presenting cardiomyopathy 
[5,12,14,27]' neurological syndromes [9, 21] or musculo-
skeletal manifestations [11, 12,35] have been reported. 
In these unusual patients, the clinical onset frequently is 
later than in the typical case of type IV disease, and 
death most often results from myocardial causes. 
Because the metabolic phenotype of the hepatic graft 
permanently remains that of the donor [33], it was ex-
pected that the transplanted liver would not accumulate 
amylopectin. This prediction was verified. However, the 
question remained whether the disease would progress 
in other enzyme deficient organ systems. A Belgian child 
who underwent liver transplantation at the age of 14 
months died of heart failure 11 months later. The etiol-
ogy was suspected to have been the amylopectin which 
was demonstrated in the myocardium postoperatively 
and at autopsy. Amylopection was also widely distri-
buted in other post mortem tissues and organs (personal 
communication Dr. Jean B. Otte, University of Louvain 
Medical School, Brussels, May 23, 1990). 
Our observations are more optimistic. There have 
been no neuromuscular complications in our patients, 
and the generally retarded growth which was character-
istic pre-transplantation has been restored toward nor-
mal in all survivors. Moreover, none of the surviving pa-
tients has had cardiac complications during 1.1 to nearly 
6 postoperative years. Because a wide variety of tissues 
collected perioperatively in different cases contained cy-
toplasmic amylopectin, it must be assumed that all of the 
hearts had involvement. This was proved in the four 
hearts studied. However, the myocardial amylopectin 
was sparse in biopsies obtained a year or more after 
transplantation. Particularly striking was the diminution 
of amylopectin in a child whose endomyocardial serial 
biopsies showed a decrease in myocardial amylopectin 
over a period of 13 months following the liver transplan-
tation. This child's older sibling whose only heart biopsy 
showed minimal heart involvement 54 months postopera-
tively is still well almost 6 years after liver transplanta-
tion. We speculate that he may have cleared amylopec-
tin from his extrahepatic tissues by the time this first 
heart biopsy was obtained. 
Finally, the possibility cannot be arbitrarily dismissed 
that chronic cyclosporine therapy was an ameliorating 
factor. This drug [20] as well as the new immunosuppres-
sive agent FK 506 [34] have hepatotrophic qualities simi-
lar to those of insulin [30] which include enrichment of 
normal hepatic glycogen stores. Both of these immuno-
suppressive drugs attach to cytosolic binding sites which 
are rich in the ubiquitous enzyme peptidyl-prolyl iso-
merase [13, 28] and both cause wide ranging imunologic 
and non-immunologic effects. The action of cyclosporine 
and FK 506 could result from peptidyl-prolyl-isomerase 
inhibition and consequent triggering of second signals 
which may variably influence many physiologic proces-
ses including carbohydrate, cholesterol, and uric acid 
metabolism [34]. 
--------~ --- ----~~-------------~ .. -~~~--~K----
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